What is HC Wainwright's Estimate for BDTX FY2024 Earnings?

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) - Equities researchers at HC Wainwright lifted their FY2024 EPS estimates for Black Diamond Therapeutics in a research report issued on Tuesday, November 5th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($1.29) per share for the year, up from their prior forecast of ($1.44). HC Wainwright currently has a "Buy" rating and a $11.00 price target on the stock. The consensus estimate for Black Diamond Therapeutics' current full-year earnings is ($1.44) per share. HC Wainwright also issued estimates for Black Diamond Therapeutics' Q4 2024 earnings at ($0.31) EPS, Q1 2025 earnings at ($0.31) EPS, Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.33) EPS and FY2025 earnings at ($1.28) EPS.

Several other equities research analysts also recently commented on BDTX. Wedbush reaffirmed an "outperform" rating and issued a $16.00 target price on shares of Black Diamond Therapeutics in a research note on Tuesday, October 8th. Raymond James started coverage on shares of Black Diamond Therapeutics in a research note on Wednesday, July 31st. They issued an "outperform" rating and a $20.00 target price for the company. Finally, Piper Sandler upped their target price on shares of Black Diamond Therapeutics from $12.00 to $15.00 and gave the company an "overweight" rating in a research note on Monday, September 23rd.

Black Diamond Therapeutics Stock Performance

NASDAQ:BDTX traded up $0.11 during trading hours on Friday, hitting $3.29. The stock had a trading volume of 535,546 shares, compared to its average volume of 819,234. Black Diamond Therapeutics has a one year low of $1.62 and a one year high of $7.66. The company has a market cap of $185.92 million, a price-to-earnings ratio of -2.19 and a beta of 2.51. The business's 50 day moving average is $4.10 and its 200-day moving average is $5.00.

Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) last issued its earnings results on Tuesday, November 5th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.09.

Institutional Investors Weigh In On Black Diamond Therapeutics

Several large investors have recently made changes to their positions in the stock. Vontobel Holding Ltd. bought a new stake in shares of Black Diamond Therapeutics during the third quarter worth $68,000. Susquehanna Fundamental Investments LLC bought a new stake in shares of Black Diamond Therapeutics during the first quarter worth $82,000. Foundations Investment Advisors LLC increased its position in shares of Black Diamond Therapeutics by 17.7% during the second quarter. Foundations Investment Advisors LLC now owns 113,550 shares of the company's stock worth $529,000 after acquiring an additional 17,050 shares in the last quarter. Acadian Asset Management LLC increased its position in shares of Black Diamond Therapeutics by 13.8% during the first quarter. Acadian Asset Management LLC now owns 170,510 shares of the company's stock worth $864,000 after acquiring an additional 20,616 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of Black Diamond Therapeutics during the second quarter worth $108,000. Institutional investors own 95.47% of the company's stock.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.